Skip to content

Study · Randomized controlled trial · n = 315 · 1993

8 results

Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group.

Rock JA, Truglia JA, Caplan RJ

Obstetrics and gynecology1 Aug 1993Cited by 60 (Europe PMC)

PMID8336864 (opens in a new tab)PepBankPUB-08336864
Publisher pageAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with endometriosis, revised AFS scores decreased by 53% with goserelin and 33% with danazol after 24 weeks.

    In plain wordsIn women with endometriosis, endometriosis scores fell by 53% with goserelin and 33% with danazol after 24 weeks.

    Peptide
    Goserelin
    Outcome
    DecreaseRevised AFS endometriosis score
    Study

    n = 315

    Outcome group
    Organ injury · Reproductive and sexual health
    Studied dose
    3.6 mg every 28 days · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    AFS score reduction
    53%
    goserelin at 24 weeks
    AFS score reduction
    33%
    danazol at 24 weeks

    Source sentences

    Summary
    The mean percent reduction in the revised AFS endometriosis score after 24 weeks of treatment was 53% for Zoladex and 33% for danazol, and reduction in the endometrial implants score was 56% for Zoladex and 46% for danazol.
    2 context sentences
    Summary · context
    To compare the efficacy, endocrine effects, and safety of Zoladex (goserelin acetate) and danazol in the treatment of premenopausal women with endometriosis in a multicenter, randomized, open study.
    Summary · context
    Three hundred fifteen patients with stages I-IV endometriosis (revised American Fertility Society [AFS] classification) were treated with Zoladex, 3.6 mg every 28 days by subcutaneous injection, or danazol, 400 mg orally twice daily for 24 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with endometriosis, endometrial implant scores decreased by 56% with goserelin and 46% with danazol after 24 weeks.

    In plain wordsIn women with endometriosis, implant scores fell by 56% with goserelin and 46% with danazol after 24 weeks.

    Peptide
    Goserelin
    Outcome
    DecreaseEndometrial implants score
    Study

    n = 315

    Outcome group
    Organ injury · Reproductive and sexual health
    Studied dose
    3.6 mg every 28 days · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Implants score reduction
    56%
    goserelin
    Implants score reduction
    46%
    danazol

    Source sentences

    Summary
    The mean percent reduction in the revised AFS endometriosis score after 24 weeks of treatment was 53% for Zoladex and 33% for danazol, and reduction in the endometrial implants score was 56% for Zoladex and 46% for danazol.
    2 context sentences
    Summary · context
    To compare the efficacy, endocrine effects, and safety of Zoladex (goserelin acetate) and danazol in the treatment of premenopausal women with endometriosis in a multicenter, randomized, open study.
    Summary · context
    Three hundred fifteen patients with stages I-IV endometriosis (revised American Fertility Society [AFS] classification) were treated with Zoladex, 3.6 mg every 28 days by subcutaneous injection, or danazol, 400 mg orally twice daily for 24 weeks.
  3. 03HumanRandomized controlled trialSafety outcome

    In women with endometriosis, hypoestrogenic effects were more frequent with goserelin than danazol.

    In plain wordsIn women with endometriosis, low-estrogen effects were more frequent with goserelin than danazol.

    Peptide
    Goserelin
    Outcome
    IncreaseHypoestrogenic effects
    Study

    n = 315

    Comparator
    Danazol
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3.6 mg every 28 days · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Hypoestrogenic effects occurred more frequently with Zoladex, whereas androgenic side effects were more common with danazol.
    2 context sentences
    Summary · context
    To compare the efficacy, endocrine effects, and safety of Zoladex (goserelin acetate) and danazol in the treatment of premenopausal women with endometriosis in a multicenter, randomized, open study.
    Summary · context
    Three hundred fifteen patients with stages I-IV endometriosis (revised American Fertility Society [AFS] classification) were treated with Zoladex, 3.6 mg every 28 days by subcutaneous injection, or danazol, 400 mg orally twice daily for 24 weeks.
  4. 04HumanRandomized controlled trialSafety outcome

    In women with endometriosis, adverse-event withdrawals were less frequent with goserelin than danazol.

    In plain wordsIn women with endometriosis, fewer patients stopped goserelin because of adverse events than stopped danazol.

    Peptide
    Goserelin
    Outcome
    DecreaseWithdrawals due to adverse events
    Study

    n = 315

    Comparator
    Danazol
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3.6 mg every 28 days · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    There was a higher percentage of withdrawals due to adverse events with danazol than with Zoladex.
    2 context sentences
    Summary · context
    To compare the efficacy, endocrine effects, and safety of Zoladex (goserelin acetate) and danazol in the treatment of premenopausal women with endometriosis in a multicenter, randomized, open study.
    Summary · context
    Three hundred fifteen patients with stages I-IV endometriosis (revised American Fertility Society [AFS] classification) were treated with Zoladex, 3.6 mg every 28 days by subcutaneous injection, or danazol, 400 mg orally twice daily for 24 weeks.
  5. 05HumanRandomized controlled trialSafety outcome

    In women with endometriosis, mean bone mineral density fell 5.4% with goserelin and rose 1.0% with danazol from baseline at treatment completion.

    In plain wordsIn women with endometriosis, bone mineral density fell 5.4% with goserelin and rose 1.0% with danazol from baseline at treatment completion.

    Peptide
    Goserelin
    Outcome
    DecreaseBone mineral density
    Study

    n = 315

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.6 mg every 28 days · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Bone mineral density change
    −5.4%
    goserelin from baseline
    Bone mineral density change
    1%
    danazol from baseline

    Source sentences

    Summary
    Mean bone mineral density decreased from baseline by 5.4% in the Zoladex group and increased by 1.0% in the danazol group at the end of treatment.
    2 context sentences
    Summary · context
    To compare the efficacy, endocrine effects, and safety of Zoladex (goserelin acetate) and danazol in the treatment of premenopausal women with endometriosis in a multicenter, randomized, open study.
    Summary · context
    Three hundred fifteen patients with stages I-IV endometriosis (revised American Fertility Society [AFS] classification) were treated with Zoladex, 3.6 mg every 28 days by subcutaneous injection, or danazol, 400 mg orally twice daily for 24 weeks.
  6. 06HumanRandomized controlled trialSafety outcome

    In women with endometriosis, androgenic side effects were less common with goserelin than danazol.

    In plain wordsIn women with endometriosis, androgen-like side effects were less common with goserelin than danazol.

    Peptide
    Goserelin
    Outcome
    DecreaseAndrogenic side effects
    Study

    n = 315

    Comparator
    Danazol
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    3.6 mg every 28 days · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Hypoestrogenic effects occurred more frequently with Zoladex, whereas androgenic side effects were more common with danazol.
    2 context sentences
    Summary · context
    To compare the efficacy, endocrine effects, and safety of Zoladex (goserelin acetate) and danazol in the treatment of premenopausal women with endometriosis in a multicenter, randomized, open study.
    Summary · context
    Three hundred fifteen patients with stages I-IV endometriosis (revised American Fertility Society [AFS] classification) were treated with Zoladex, 3.6 mg every 28 days by subcutaneous injection, or danazol, 400 mg orally twice daily for 24 weeks.
  7. 07HumanNon-randomized trialEfficacy outcome

    In women with endometriosis, goserelin significantly reduced mean subjective signs and symptoms scores during and after therapy.

    In plain wordsIn women with endometriosis, goserelin reduced symptom scores during and after treatment.

    Peptide
    Goserelin
    Outcome
    DecreaseSubjective signs and symptoms
    Study

    n = 315

    Outcome group
    Organ injury · Reproductive and sexual health
    Studied dose
    3.6 mg every 28 days · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Both treatments significantly (P < .0001) reduced mean subjective signs and symptoms scores both during and after therapy.
    2 context sentences
    Summary · context
    To compare the efficacy, endocrine effects, and safety of Zoladex (goserelin acetate) and danazol in the treatment of premenopausal women with endometriosis in a multicenter, randomized, open study.
    Summary · context
    Three hundred fifteen patients with stages I-IV endometriosis (revised American Fertility Society [AFS] classification) were treated with Zoladex, 3.6 mg every 28 days by subcutaneous injection, or danazol, 400 mg orally twice daily for 24 weeks.
  8. 08HumanNon-randomized trialActivity measurement

    In women with endometriosis, goserelin reduced serum estradiol to the postmenopausal range.

    In plain wordsIn women with endometriosis, goserelin reduced estradiol to the postmenopausal range.

    Peptide
    Goserelin
    Outcome
    DecreaseSerum estradiol
    Study

    n = 315

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    3.6 mg every 28 days · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Serum estradiol levels decreased to the postmenopausal range in the Zoladex group and to the early follicular phase range in the danazol group.
    2 context sentences
    Summary · context
    To compare the efficacy, endocrine effects, and safety of Zoladex (goserelin acetate) and danazol in the treatment of premenopausal women with endometriosis in a multicenter, randomized, open study.
    Summary · context
    Three hundred fifteen patients with stages I-IV endometriosis (revised American Fertility Society [AFS] classification) were treated with Zoladex, 3.6 mg every 28 days by subcutaneous injection, or danazol, 400 mg orally twice daily for 24 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.